date:Dec 24, 2012
that was FDA-approved for the treatment of obesity.
It is Schedule IV controlled substance and because of the risks associated with its use, it should be taken only under the direct supervision of qualified health care professional.
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk to patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. Sibutramine has been withd